NEW YORK (GenomeWeb News) – Investment bank Jefferies this week upgraded Bruker's stock to Buy from Hold and upped its price target on the stock from $20 to $25. "We have increased confidence in [Bruker's] intermediate-term profit and cash flow trajectories, and see more than [an] adequate degree of conservatism in its formal 2013 outlook," Jefferies analyst Jon Wood wrote in a note published Thursday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.